肿瘤细胞治疗研究
英文原题：Targeting CD38 for acute leukemia.
急性白血病（AL）是一种血液系统恶性肿瘤，大多数 AL 患者的预后未得到显著改善，尤其是复发或难治性（R/R）AL。
急性白血病（AL）是一类血液系统恶性肿瘤，多数AL患者预后并未显著改善，复发/难治性（R/R）患者尤为如此。因此，亟需为成人R/R急性髓系白血病（AML）和急性淋巴细胞白血病（ALL）开发新疗法。AL治疗近期出现了靶向治疗和免疫治疗等新进展。CD38在多种血液系统恶性肿瘤（包括多发性骨髓瘤、ALL及部分AML）中高表达，因此成为治疗靶点之一。靶向CD38疗法包括CD38单克隆抗体（mAb）、双特异性抗体和CAR-T细胞治疗；这些方法治疗多发性骨髓瘤时疗效良好且无明显毒性，现正拓展至其他血液系统恶性肿瘤和非血液系统疾病。本文重点综述靶向CD38治疗ALL和AML的策略，这些疗法在急性白血病中显示出良好抗白血病作用，有望成为有效治疗手段。
Acute leukemia (AL) is a hematological malignancy, and the prognosis of most AL patients hasn't improved significantly, particularly for relapsed or refractory (R/R) AL. Therefore, new treatments for R/R adult acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are urgently necessary. Novel developments have been made in AL treatment, including target and immune therapies. CD38 is one of the targets due to its high expression in many hematological malignancies, including multiple myeloma, ALL and a subset of AML. Consequently, targeting CD38 therapies, including CD38 monoclonal antibodies (mAbs), bispecific antibodies, and CAR-T cell therapy, exhibit promising efficacy in treating multiple myeloma without significant toxicity and are being explored in other hematological malignancies and nonhematological diseases. Herein, this review focuses on targeting CD38 therapies in ALL and AML, which demonstrate sound antileukemic effects in acute leukemia and are expected to become effective treatment methods.
MEMBER ACCOUNT
登录成功会直接打开下一页。
